IL1A and neoplasm: Anakinra as a single agent was shown to suppress tumor growth of IL-1-producing, but not non-IL-1-producing, tumor cell lines [27] and anakinra has been shown to be effective in combination with other anti-tumor agents in various other disease models [32–35].